EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy

Saryleine de Ortiz de Choudens iD, Alexis Visotcky, Anjishnu Banerjee, Mohammed Aldakkak, Susan Tsai iD, Douglas B Evans, Kathleen K Christians, Callisia N Clarke, Ben George, Aditya Shreenivas, Mandana Kamgar iD, Sakti Chakrabarti und 5 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.6582 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Saryleine de Ortiz de Choudens und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Fluorouracil. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose/Objectives Most patients with pancreatic adenocarcinoma (PDAC) will present with distant metastatic disease at diagnosis. We sought to identify clinical characteristics associated with prolonged overall survival (OS) in patients presenting with metastatic PDAC. Materials/Methods Patients presenting with metastatic PDAC that received treatment at our institution with FOLFIRINOX or gemcitabine‐based chemotherapies between August 1, 2011 and September 1, 2017 were included in the study. Metastatic disease burden was comprehensively characterized radiologically via individual diagnostic imaging segmentation. Landmark analysis was performed at 18 months, and survival curves were estimated using the Kaplan–Meier method and compared between groups via the log‐rank test. ECOG and Charlson Comorbidity Index (CCI) were calculated for all patients.

Results

121 patients were included with a median age of 62 years (37–86), 40% were female, 25% had ECOG 0 at presentation. Of the 121 patients included, 33% ( n = 41) were alive at 12 months and 25% ( n = 31) were alive at 18 months. Landmark analysis demonstrated a significant difference between patients surviving 60 cc, p = 0.004), metastasis only in the liver ( p = 0.04), and normalization of CA 19‐9 ( p < 0.001). At Year 2, the only predictor of improved OS was normalization of the CA 19‐9 ( p = 0.03). In those patients that normalized their CA 19‐9, median overall survival was 16 months.

Conclusions

In this exploratory analysis normalization of CA‐19‐9 or volumetric metastatic disease burden less than 0.2 cc demonstrated a remarkable OS, similar to that of patients with non‐metastatic disease. These metrics are useful for counseling patients and identifying cohorts that may be optimal for trials exploring metastatic and/or local tumor‐directed interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsLeucovorinFluorouracilAdenocarcinomaHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and overDeoxycytidineGemcitabineIrinotecanRetrospective StudiesOxaliplatinNeoplasm MetastasisKaplan-Meier EstimateLung NeoplasmsPrognosis

Stichwörter der Autor:innen

neoplasm metastasisoligometastasispancreatic neoplasms

Substanzen

LeucovorinFluorouracilfolfirinoxDeoxycytidineGemcitabineIrinotecanOxaliplatin

Autor:innen und Institutionen

  • Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • LaBahn Pancreatic Cancer Program, Milwaukee, Wisconsin, USA.
  • Division of Medical Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Division of Gastroenterology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

ORCID-Profile: Saryleine de Ortiz de Choudens, Susan Tsai, Mandana Kamgar, William A Hall

Förderung

  • NCATS NIH HHS

Zitieren

APA

de Ortiz de Choudens, S., Visotcky, A., Banerjee, A., Aldakkak, M., Tsai, S., Evans, D. B., Christians, K. K., Clarke, C. N., George, B., Shreenivas, A., Kamgar, M., Chakrabarti, S., Dua, K. S., Khan, A. H., Madhavan, S., Erickson, B. A., & Hall, W. A. (2024). Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy. Cancer Medicine. https://doi.org/10.1002/cam4.6582

Vancouver

de Ortiz de Choudens S, Visotcky A, Banerjee A, Aldakkak M, Tsai S, Evans DB, et al. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy. Cancer Medicine. 2024. doi:10.1002/cam4.6582

BibTeX
@article{deOrtizdeChoudens2024,
  author = {de Ortiz de Choudens, Saryleine and Visotcky, Alexis and Banerjee, Anjishnu and Aldakkak, Mohammed and Tsai, Susan and Evans, Douglas B and Christians, Kathleen K and Clarke, Callisia N and George, Ben and Shreenivas, Aditya and Kamgar, Mandana and Chakrabarti, Sakti and Dua, Kulwinder S and Khan, Abdul Haq and Madhavan, Srivats and Erickson, Beth A and Hall, William A},
  title = {Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6582}
}
Kostenlos starten →